Anguille S, et al. - The authors performed this phase II study to examine the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) mRNA as post-remission treatment in acute myeloid leukemia (AML) patients at very high risk of relapse. After standard chemotherapy, vaccination of AML patients with WT1 mRNA-electroporated DCs could be an effective strategy to prevent or delay relapse, translating into improved overall survival (OS) rates, which were associated with the induction of WT1-specific CD8+ T-cell response.